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DISCUSSION
Dr Hugh A. Gelabert (Los Angeles, Calif). I wish to thank
the authors for kindly remitting a copy of their manuscript in a
timely manner. It is well written and clearly illustrated and for this
I commend them.
The success of drug eluting stents has provided the impetus for
this project, where drug-eluting mesh is used to modulate the
hyperplasia response in a sheep model of AV graft dialysis access.
An absorbable mesh was impregnated with paclitaxel (an agent
which inhibits angiogenesis and smooth muscle proliferation) and
this was wrapped around the venous anastomosis of a PTFE AV
graft. The animals were followed for about 2 months, then eutha-
nized.
The anastomoses were studied to assess diameter reduction
and histological characteristics. The findings indicate a statistically
significant reduction in the intimal hyperplasia at the venous anas-
tomosis in the treated subjects. Concerns include the small number
of subjects, the limited extent of the study period, and the limited
parameters studied in this experiment. Still the findings are encour-
aging and merit further investigation.
Question one, the authors indicate that paclitaxel has been
shown to inhibit neutrophil and lymphocyte activation, yet they
claim there was no dose effect on perigraft inflammation. Please
comment.
Question two, in the course of the experiment, five subjects
were lost, as their AV grafts clotted. Were any of the clotted grafts
subject to histological or morphometric analysis to assess intimal
hyperplasia in these failures?
Question three, given the described effects of paclitaxel—the
inhibition of neutrophils, lymphocytes, macrophages, smooth
muscle cells, and capillary growth—what is the chance of increased
prosthetic graft infections?
Dr Ted Kohler. Thank you Hugh, for a very thoughtful
review and for your excellent questions. First, regarding the effects
of paclitaxel on inflammation. We did note that there were fewer
macrophages associated with the wrap in the drug-treated groups
and that resorption of the wrap was delayed. We did not note a
dose-effect escalation of these effects as the dose increased. This
either may be because our lowest dose was already producing the
maximum anti-inflammatory effect, or it could be related to the
rather crude qualitative measures we had for this effect, which was
not a primary focus of this study.
Next, with regard to the failed grafts, gross inspection deter-
mined a kink in one graft but no obvious cause of the failure of the
other devices. We have found that it is not possible to determine
the cause of failure using microscopic histology of clotted grafts:
the histology is too distorted by the thrombus. The neck of the
sheep is long and flexible, which makes these grafts prone to
kinking. Early on, we removed the external ring support of the
devices too far back from the venous anastomosis, and this may
have contributed to kinking. The relatively early timing of these
failures makes intimal hyperplasia an unlikely cause, and our find-
ing of reduced mural thrombus in the drug-treatment groups at 8
weeks makes primary thrombosis seem unlikely. The failure rate
the current experimental group was very similar to that we ob-
served in our initial description of this model. Further, there was
not a statistically significant difference between drug and control
groups, although the numbers are too small for valid statistical
comparison.
Finally, as far as I know, there have been no observations of
increased infections in any of the many applications of paclitaxel.
The slower resorption of the mesh along with inhibition of inflam-
mation could theoretically increase the risk of infection. One nice
aspect of this local approach is that the drug affects only a short
segment of the graft at the venous anastomosis, where infection is
rarely a problem. It is comforting to note that we did not observe
infections in our model, but the numbers are relatively small. The
drug is gone by a few weeks, so normal inflammatory processes
should resume by that time (hopefully not contributing to intimal
hyperplasia!). This question and the efficacy of this novel treatment
in patients will be addressed in a large clinical trial that is currently
being designed.
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Dr James Watson (Seattle, Wash). That is a nice study, Ted.
I just have a question. I have to apologize for my ignorance, but
after the paclitaxel runs out, does it still confer protection against
development of neointimal hyperplasia? In other words, will both
groups start at the same rate after the paclitaxel runs out, and if so,
do you need to consider a better way to provide long-term protec-
tion with paclitaxel?
Dr Kohler. That is a great question. As I mentioned in the
coronary stent trials, patients maintain the benefit as long as 4 years
but that is a very different situation. In the coronary stent where
the neointima once it matures and perhaps endothelializes, then
the patient is no longer at risk, whereas in dialysis access grafts, as
we all know, there is an ongoing injury at that venous end. The
hope is that if the neointima can form, mature and become more
stable that it will be less prone to continue to stenose but that may
not be the case and that is why we need the longer-term studies.
Also, PTFE has such a poor patency rate that even if we could
get 6 or 8 months more out of this treatment, it would be a
significant difference and I think a clinically meaningful difference.
Wemay very well wish to go to a PTFE forearm loop before having
to go to a basilica transposition which is a much bigger deal for our
patients. With dialysis access, it is all about buying time.
Dr Watson.Do you know if there is a potential for longer time
paclitaxel elution? In other words, can you put something in that will
give the drug for a long period of time or does that have its own. . .
Dr Kohler. There are local delivery devices that Steve (Han-
sen) has developed that could be used. The elution rate can be
adjusted with this bioresorbable but not beyond a couple of
months, so unless Rui Avelar has some trick up his sleeve that he
has not told me yet, I think we are going to be limited in that
respect.
Audience. That is a nice paper, Ted. I was going to ask you
about the elution kinetics as well. Can the PTFE actually elute the
paclitaxel? Is that an option rather than having the mesh be placed
externally and also bioabsorbable stents possibly or some variant of
that. How do you move from the model to a clinically practical
application?
Dr Kohler. Those are great thoughts as well. We have talked
about putting the drug directly into the PTFE.We are interested in
doing that in 60-micron PTFE grafts, which have a lot more space
within the graft material. The commercially available 20- to 30-
micron grafts do not have as much space within the intranodal
space to have drug, but it may be that having drug there is all we
need. I like the idea of the wrap around the vein because that is the
source for this neointima that is growing in. Actually the wrap is
extremely simple to use so in terms of clinical application I think
this is a extremely simple procedure to simply place the wrap and
that is what the next clinical trial is going to be, but we are always
thinking of other ways to deliver the drug.
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